University of Health Sciences Turkey, Ankara Dr. Sami Ulus Obstetrics and Gynecology, Children’s Health and Diseases Training and Research Hospital, Clinic of Pediatric Endocrinology, Ankara, Turkey
Ankara University Faculty of Medicine, Department of Pediatric Endocrinology, Ankara, Turkey
J Clin Res Pediatr Endocrinol. 2021 Aug 23;13(3):332-341. doi: 10.4274/jcrpe.galenos.2021.2020.0238. Epub 2021 Mar 22.
The aim was to evaluate the results of diagnosis, follow-up and treatment of the patients who recieved growth hormone (GH) treatment for the last 10 years and to determine the differences in the process and results over the years.
Anthropometric, clinical, laboratory data, treatment adherence and side effects were evaluated retrospectively in 767 patients who recieved GH treatment between 2009-2018. Patients were grouped as isolated GH deficiency (IGHD), multiple pituitary hormone deficiency (MPHD), small for gestational age (SGA), and Turner syndrome (TS) depending on diagnosis.
GH treatment was started in 689 cases (89.8%) with IGHD, 24 (3.1%) with MPHD, 26 (3.4%) with SGA and 28 (3.7%) with TS. Median age of GH treatment onset was the earliest in SGA (8.4 years) and the latest in the IGHD group (12.0 years). At the time of treatment cessation, height standard deviation score (SDS) in IGHD and MPHD was significantly higher than treatment initiation time, whereas there was no significant difference in TS and SGA. One hundred eighty-nine cases reached the final height. Final heights for girls/boys were: IGHD 154/164.9 cm; MPHD 156.2/163.5 cm; TS 146.7 cm; and SGA 145.7/-cm, respectively. Target height SDS-final height SDS median values were IGHD: 0.1, MPHD: 0.6, SGA: 0.5, TS: 2.4 respectively. The patients’ treatment compliance was high (92%) and the incidence of side effects was low (2.7%).
In our cohort, GH treatment start age was late and no difference in this was observed in the last 10 years. The improvement in the height SDS was most marked in the IGHD and MPHD groups, the least in the TS and SGA groups.
评估过去 10 年接受生长激素（GH）治疗的患者的诊断、随访和治疗结果，并确定多年来该过程和结果的差异。
回顾性评估 2009 年至 2018 年间接受 GH 治疗的 767 例患者的人体测量、临床、实验室数据、治疗依从性和副作用。根据诊断，患者分为孤立性生长激素缺乏症（IGHD）、多种垂体激素缺乏症（MPHD）、小于胎龄儿（SGA）和特纳综合征（TS）。
689 例（89.8%）患者开始 GH 治疗，IGHD 24 例（3.1%），MPHD 26 例（3.4%），SGA 28 例（3.7%），TS 28 例（3.7%）。GH 治疗开始的中位年龄在 SGA 中最早（8.4 岁），在 IGHD 组中最晚（12.0 岁）。在治疗停止时，IGHD 和 MPHD 的身高标准差评分（SDS）明显高于治疗开始时，而 TS 和 SGA 则无明显差异。189 例达到最终身高。女孩/男孩的最终身高分别为：IGHD 154/164.9cm；MPHD 156.2/163.5cm；TS 146.7cm；SGA 145.7/-cm。靶身高 SDS-最终身高 SDS 的中位数分别为 IGHD：0.1，MPHD：0.6，SGA：0.5，TS：2.4。患者的治疗依从性高（92%），副作用发生率低（2.7%）。
在我们的队列中，GH 治疗开始年龄较晚，在过去 10 年中没有差异。IGHD 和 MPHD 组的身高 SDS 改善最明显，TS 和 SGA 组改善最不明显。
